Fursultiamine
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | None |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | 804-30-8 |
PubChem (CID) | 3002119 |
DrugBank | DB08966 |
ChemSpider | 2273321 |
UNII | 05J61265PX |
ChEMBL | CHEMBL1740659 |
ECHA InfoCard | 100.011.234 |
Chemical and physical data | |
Formula | C17H26N4O3S2 |
Molar mass | 398.54 g/mol |
3D model (Jmol) | Interactive image |
|
Fursultiamine (INN; Adventan, Alinamin-F, Benlipoid, Bevitol Lipophil, Judolor), also known as thiamine tetrahydrofurfuryl disulfide (TTFD), is a disulfide derivative of thiamine, or an allithiamine.[1] It was synthesized in Japan in the 1960s for the purpose of developing forms of thiamine with improved lipophilicity for treating vitamin B1 deficiency (i.e., beriberi),[1][2] and was subsequently commercialized not only in Japan but also in Spain, Austria, Germany, and the United States.[3] As a vitamin, it is available over-the-counter as well.[4]
In addition to its clinical indication of avitaminosis, fursultiamine has been studied in clinical trials for Alzheimer's disease and autistic spectrum disorders with positive but modest benefits.[5][6] It has also been investigated in improving energy metabolism during exercise and reducing exercise-induced fatigue with conflicting results.[4][7][8][9]
Available Brands: Privitamix softgel (India)
See also
References
- 1 2 Lonsdale D (September 2004). "Thiamine tetrahydrofurfuryl disulfide: a little known therapeutic agent". Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 10 (9): RA199–203. PMID 15328496.
- ↑ Miura S (July 1965). "[The uptake and the distribution of thiamine propyl disulfide-35S by the rabbit's eye tissue]". Nippon Ganka Gakkai Zasshi (in Japanese). 69 (7): 792–807, discussion 807–8. PMID 5006719.
- ↑ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. p. 1932. ISBN 3-88763-075-0.
- 1 2 Nozaki S, Mizuma H, Tanaka M, et al. (December 2009). "Thiamine tetrahydrofurfuryl disulfide improves energy metabolism and physical performance during physical-fatigue loading in rats". Nutrition Research (New York, N.Y.). 29 (12): 867–72. doi:10.1016/j.nutres.2009.10.007. PMID 19963160.
- ↑ Mimori Y, Katsuoka H, Nakamura S (March 1996). "Thiamine therapy in Alzheimer's disease". Metabolic Brain Disease. 11 (1): 89–94. doi:10.1007/BF02080934. PMID 8815393.
- ↑ Lonsdale D, Shamberger RJ, Audhya T (August 2002). "Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study". Neuro Endocrinology Letters. 23 (4): 303–8. PMID 12195231.
- ↑ Suzuki M, Itokawa Y (March 1996). "Effects of thiamine supplementation on exercise-induced fatigue". Metabolic Brain Disease. 11 (1): 95–106. doi:10.1007/bf02080935. PMID 8815395.
- ↑ Webster MJ, Scheett TP, Doyle MR, Branz M (1997). "The effect of a thiamin derivative on exercise performance". European Journal of Applied Physiology and Occupational Physiology. 75 (6): 520–4. doi:10.1007/s004210050198. PMID 9202948.
- ↑ Masuda H, Matsumae H, Masuda T, Hatta H (2010). "A thiamin derivative inhibits oxidation of exogenous glucose at rest, but not during exercise". Journal of Nutritional Science and Vitaminology. 56 (1): 9–12. doi:10.3177/jnsv.56.9. PMID 20354340.
Further reading
- Lonsdale D (September 2004). "Thiamine tetrahydrofurfuryl disulfide: a little known therapeutic agent". Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 10 (9): RA199–203. PMID 15328496.